Prompt benefit of early immunosuppressive therapy in acute lymphocytic myocarditis with persistent heart failure

Clinical Research in Cardiology

Volumn 105, Issue 9, 2016, Pages 794-796

  Weitsman, Tatyana ^a   Weisz, Giora ^a   Keren, Andre ^b   Hasin, Tal ^a  

^a SHAARE ZEDEK MEDICAL CENTER   (Israel)

^b HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; BISOPROLOL; FUROSEMIDE; LOSARTAN; PREDNISONE; SPIRONOLACTONE; IMMUNOSUPPRESSIVE AGENT;

ADULT; CARDIOVASCULAR MAGNETIC RESONANCE; CASE REPORT; DYSPNEA; ECHOCARDIOGRAPHY; FEMALE; GASTROENTERITIS; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE BIOPSY; HUMAN; HUMAN TISSUE; HYPERTRANSAMINASEMIA; IMMUNOSUPPRESSIVE TREATMENT; LETTER; LYMPHOCYTIC MYOCARDITIS; MIDDLE AGED; MITRAL VALVE REGURGITATION; MYOCARDITIS; NAUSEA; SINUS TACHYCARDIA; THORAX RADIOGRAPHY; TRICUSPID VALVE REGURGITATION; WEAKNESS; BIOPSY; CARDIAC MUSCLE; COMBINATION DRUG THERAPY; CONVALESCENCE; DRUG EFFECTS; IMMUNOLOGY; LYMPHOCYTE; PATHOLOGY; PATHOPHYSIOLOGY; TIME FACTOR; TREATMENT OUTCOME;

ADULT; AZATHIOPRINE; BIOPSY; DRUG THERAPY, COMBINATION; FEMALE; HEART FAILURE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LYMPHOCYTES; MYOCARDITIS; MYOCARDIUM; PREDNISONE; RECOVERY OF FUNCTION; TIME FACTORS; TREATMENT OUTCOME;

EID: 84964374927     PISSN: 18610684     EISSN: 18610692     Source Type: Journal    
DOI: 10.1007/s00392-016-0985-x     Document Type: Letter

References (9)

1. Caforio AL, Pankuweit S, Arbustini E, Basso C, Gimeno-Blanes J, Felix SB, et al. (2013) Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J 34(33):2636–48, 48a–48d
2. Caforio AL, Calabrese F, Angelini A, Tona F, Vinci A, Bottaro S et al (2007) A prospective study of biopsy-proven myocarditis: prognostic relevance of clinical and aetiopathogenetic features at diagnosis. Eur Heart J 28(11):1326–1333
3. Caforio AL, Goldman JH, Haven AJ, Baig KM, McKenna WJ (1996) Evidence for autoimmunity to myosin and other heart-specific autoantigens in patients with dilated cardiomyopathy and their relatives. Int J Cardiol 54(2):157–163
4. Rose NR (2000) Viral damage or ‘molecular mimicry’—placing the blame in myocarditis. Nat Med 6(6):631–632
5. Mason JW, O’Connell JB, Herskowitz A, Rose NR, McManus BM, Billingham ME et al (1995) A clinical trial of immunosuppressive therapy for myocarditis. The Myocarditis Treatment Trial Investigators. N Engl J Med 333(5):269–275
6. Frustaci A, Chimenti C, Calabrese F, Pieroni M, Thiene G, Maseri A (2003) Immunosuppressive therapy for active lymphocytic myocarditis: virological and immunologic profile of responders versus nonresponders. Circulation 107(6):857–863
7. Heart Failure Society of America (2000) HFSA guidelines for management of patients with heart failure caused by left ventricular systolic dysfunction—pharmacological approaches. Pharmacotherapy 20(5):495–522
8. Feldman AM, McNamara D (2000) Myocarditis. N Engl J Med 343(19):1388–1398
9. Frustaci A, Russo MA, Chimenti C (2009) Randomized study on the efficacy of immunosuppressive therapy in patients with virus-negative inflammatory cardiomyopathy: the TIMIC study. Eur Heart J 30(16):1995–2002